首页|基于全血稳定性研究的利奈唑胺治疗药物监测的临床采样流程建立

基于全血稳定性研究的利奈唑胺治疗药物监测的临床采样流程建立

扫码查看
目的:建立HPLC法测定人血浆中利奈唑胺浓度,完善其全血稳定性研究并制订临床采样流程,以期为利奈唑胺治疗药物监测(therapeutic drug monitoring,TDM)及个体化给药方案设计提供参考,促进抗感染药物TDM体系的规范化与标准化建设。方法:血浆样品加入内标物(头孢哌酮)经乙腈(含0。1%甲酸)沉淀蛋白,取上清液-水(1∶1,V/V)稀释后进样;以50 mmol·L-1 磷酸二氢钾溶液(含0。05%甲酸)-乙腈(75∶25,V/V)为流动相,经Shim-pack GIST C18(4。6 mm×250 mm,5。0 µm)分离,流速:1。0 mL·min-1,检测波长:254 nm,柱温:40 ℃,分别考察利奈唑胺全血、血浆样本在不同温度、不同采血管等条件下的稳定性,基于全血稳定性结果制订临床采样及送检流程,并应用于临床TDM。结果:利奈唑胺在0。59~23。40µg·mL-1范围内线性关系良好(r2>0。999),定量下限为0。59 µg·mL-1,低、中、高浓度的萃取回收率在95。97%~111。35%范围内,日内、日间精密度RSD均小于8。72%;肝素钠采血管的全血样本于室温(18~23 ℃)、4 ℃冰箱24 h内稳定,优于同等放置条件下EDTA-K2采血管(12h内稳定),血浆质控样品经预处理后于自动进样器(6℃)24h稳定,血浆质控样品于4℃冰箱、室温(18~23℃)24h、-80℃冻存65 d、-80 ℃反复冻融3次均稳定。结论:建立的利奈唑胺TDM方法及临床采样流程能确保利奈唑胺的稳定性及检测结果的准确性,为利奈唑胺的TDM标准化与规范化建设提供参考依据。
Establishment of clinical sampling process for therapeutic drug monitoring of linezolid based upon whole blood stability studies
OBJECTIVE To establish a high performance liquid chromatography(HPLC)method for measuring linezolid in human plasma and create a clinical sampling process based upon a whole blood stability study to enhance the comprehensive investi-gation of whole blood stability and advance the clinical sampling procedure,offering references for precise linezolid therapeutic drug monitoring(TDM)and personalized drug dosing scheme formulation,as well as fostering the standardization and uniformity of anti-infective drug TDM system.METHODS Plasma samples were treated with an internal standard(cefoperazone)and pre-cipitated with a solution of acetonitrile(0.1%formic acid).The supernatant was diluted with water(1∶1,V/V)and subsequently loaded.Separation of the components was achieved on a Shim-pack GIST C18 column(4.6 mm×250 mm,5.0 μm)with a mobile phase consisting of 50 mmol·L-1 potassium dihydrogen phosphate containing 0.05%formic acid-acetonitrile(75∶25,V/V).Flow rate was set at 1.0 mL·min-1.Detection was performed at a wavelength of 254 nm and a column temperature of 40 ℃.The study examined the stability of linezolid in whole blood and plasma samples under varying temperatures and sampling vessels.Based upon the findings from the analysis of whole blood stability,the development of clinical sampling and testing protocols and the clinical implementation of TDM were implemented.RESULTS The concentration range of linezolid exhibited a strong linear relationship within a range of 0.59-23.40 μg·mL-1(r2>0.999).The lower limit of quantization was 0.59 μg·mL-1.The extraction recoveries for low,medium and high concentrations were 95.97%-111.35%.Additionally,intraday and daytime pre-cision RSD values were<8.72%.The linezolid in whole blood samples in heparin sodium collection tubes remained stable within 24 h at room temperature(18-23 ℃)and in a 4 ℃ refrigerator.It was superior to EDTA-K2 collection tubes under the same con-ditions(stable within 12 h).Additionally,plasma quality control samples underwent pretreatment and stabilization in an automatic injector at 6℃ for 24 h.Plasma samples remained stable when stored at 4 ℃,room temperature(18-23 ℃)for 24 h,frozen at-80 ℃ for 65 days and subjected to freeze-thaw cycles at-80 ℃ for 3 times.CONCLUSION The utilization of the established linezolid TDM method and clinical sampling process can effectively maintain the stability of linezolid and enhance the precision of test outcomes.Furthermore,these practices may offer valuable references for the standardization and harmonization of linezolid TDM procedures.

linezolidtherapeutic drug monitoringwhole blood stabilityclinical sampling processHPLC

乔勇、徐兵、童焕、邓阳、向德标、袁芳、李昕

展开 >

长沙市第三医院药学部,湖南长沙 410015

长沙市抗菌药物临床应用研究所,湖南长沙 410015

抗耐药微生物药物湖南省重点实验室,湖南长沙 410015

利奈唑胺 治疗药物监测 全血稳定性 临床采样流程 高效液相色谱

2024

中国医院药学杂志
中国药学会

中国医院药学杂志

CSTPCD北大核心
影响因子:1.198
ISSN:1001-5213
年,卷(期):2024.44(23)